|
 |
||||||||
 |
PRESS RELEASES ADVENTRX Pharmaceuticals to Present at CIBC World Markets 15th Annual Healthcare Conference SAN DIEGO – November 3 – ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it will present at the CIBC World Markets 15th Annual Healthcare Conference on Wednesday, November 10th. Evan M. Levine, President and CEO, will present a corporate overview and discuss the current clinical strategy for CoFactor . The presentation is scheduled for 2:30 pm eastern time at the Plaza Hotel in New York City. The Food and Drug Administration (FDA) recently granted the Company clearance to begin recruiting an additional 25 patients for the second stage of its Phase II trial using CoFactor™ to modulate the effect of 5-fluorouracil (5-FU) for metastatic colorectal cancer. About ADVENTRX ADVENTRX Pharmaceuticals, Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses on cancer and viral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. More information can be found on the Company's website at www.adventrx.com. Forward Looking Statement This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration and other regulatory agencies. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. ADVENTRX Pharmaceuticals Andrea Lynn, 858-552-0866 or CEOcast, Inc. Kevin Theiss, 212-732-4300 |
